Two Single-Arm, Multicenter Phase-Ii Trials Of Pd-1 Inhibitors In Patients With Pulmonary Sarcomatoid Carcinoma (Ncch1603/Ncch1703)

R. Toyozawa,K. Itahashi,Y. Goto, Y. Fujiwara,Y. Okuma,T. Kurata,T. Yokoyama,H. Nokihara, T. Yokoi,T. Yamaguchi,Y. Shiraishi,M. Takeda,T. Tokito,A. Nakamura,Y. Hosomi,Y. Ohe

ANNALS OF ONCOLOGY（2021）

引用 0|浏览8

暂无评分

摘要

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer, occurring in <1% of all lung tumors. PSC is highly resistant to conventional cytotoxic chemotherapies and confers a poor prognosis. Two single-arm, multicenter phase-II trials were conducted to evaluate the efficacy and safety of PD-1 inhibitors in patients with PSC.

查看译文

关键词

pulmonary sarcomatoid carcinoma,inhibitors,single-arm

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要